

DON'T MISS A DIAGNOSIS.



Early pathogen identification in patients with respiratory infections can help minimize unnecessary antibiotics and downstream procedures.

When used together, **BIOFIRE® FILMARRAY® Pneumonia (PN) Panel / BIOFIRE® Respiratory 2.1 (RP2.1) Panel with VIDAS® B•R•A•H•M•S PCT™** may help improve patient outcomes by:



Identifying the presence of **bacterial co-infections**^{1,3}



17.9X increase in neuraminidase use in the ED⁴



Reducing IV antibiotics use by **4.4 days**⁴



1.9X increase in stopping or de-escalating antibiotics⁴

BIOFIRE® PN PANEL

US FDA-cleared  2797

Identifies 33 targets including bacteria, viruses, and antimicrobial resistance genes, in about an hour.



Identifies many of the most common pathogens in community and hospital acquired pneumonia



Supports two sample types: BAL-like (including BAL and mini-BAL) and sputum-like (including ETA) samples



BAL-like 96.2% sensitivity, 98.3% specificity; Sputum-like 96.3% sensitivity, 97.2% specificity⁵

BIOFIRE® RP2.1 PANEL

US FDA-cleared

Targets 22 pathogens, including bacteria and viruses, in about 45 minutes.



Identifies a comprehensive grouping of relevant pathogens, including SARS-CoV-2



SARS-CoV-2 98.4% PPA and 98.9 NPA⁶



Overall 97.1% sensitivity and 99.3% specificity⁷

VIDAS® B•R•A•H•M•S PCT™

Detects procalcitonin, a specific marker of severe bacterial infection and sepsis, in only 20 minutes.



Aids in decision making on antibiotic therapy for patients with lower respiratory tract infections



Helps in assessing the severity and prognosis of an infection



89% sensitivity and 94% specificity for determining bacterial infection⁸

*Patient population had a mean age of 81.2 years.

1. Kyriazopoulou et. al. BioFire FilmArray Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial. Infect Dis Ther. 2021 10:1437-1449. 2. Poole S, et. al. Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: results of a randomised controlled trial. Journal of Infection (2022), doi: <https://doi.org/10.1016/j.jinf.2022.09.003>. 3. Moradi T, et. al. Use of Procalcitonin and a Respiratory Polymerase Chain Reaction Panel to Reduce Antibiotic Use via an Electronic Medical Record Alert. Clin Infect Dis. 2020 Oct 23;71(7):1684-1689. doi: [10.1093/cid/ciz1042](https://doi.org/10.1093/cid/ciz1042). PMID: 31637442; PMCID: PMC7108168. 4. Lee C-C, et. al. Combining Procalcitonin and Rapid Multiplex Respiratory Virus Testing for Antibiotic Stewardship in Older Patients With Severe Acute Respiratory Infection. JAMA. Jan;21(1):62-67. 5. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Pneumonia Panel, data on file, BioFire Diagnostics. 6. Overall performance based on prospective clinical study for the BIOFIRE® FILMARRAY® Respiratory 2 Panel, data on file, BioFire Diagnostics. 7. Overall performance based on prospective SARS-CoV-2 clinical study for the BIOFIRE® Respiratory 2.1 Panel in comparison to 3 EUA tests, data on file, BioFire Diagnostics. 8. Meisner M. Procalcitonin-biochemistry and clinical diagnosis. Dresden (Germany): UNI-MED-Verlag; 2010.

Product availability varies by country. Consult your bioMérieux representative.

©2022 bioMérieux, S.A. • BIOMÉRIEUX, the BIOMÉRIEUX logo, BIOFIRE, FILMARRAY, and VIDAS are used pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies. • B•R•A•H•M•S PCT™ is the property of Thermo Fisher Scientific, Inc. and its subsidiaries.